ArticleInfection and immunity1997
Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses.
Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 102 citations in OpenAlex.
- T-cell subsets inClinical & translational immunology · 2025Review
- IFN-γ Limits Immunopathogenesis but Delays Fungal Clearance during Pneumocystis Pneumonia.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Metabolomic Profiling of Lungs from Mice Reveals the Variability of Metabolites inJournal of inflammation research · 2023Article
- Bias of the Immune Response toJournal of fungi (Basel, Switzerland) · 2021Article
- Immune Response inJournal of fungi (Basel, Switzerland) · 2021Review
- Review
- Single-Cell TCR Sequencing Reveals the Dynamics of T Cell Repertoire Profiling DuringFrontiers in microbiology · 2021Article
- Circulating and Pulmonary T-cell Populations Driving the Immune Response in Non-HIV Immunocompromised Patients withInternational journal of medical sciences · 2019Article
- The trophic life cycle stage of Pneumocystis species induces protective adaptive responses without inflammation-mediated progression to pneumonia.Medical mycology · 2018Article
- New advances in understanding the host immune response to Pneumocystis.Current opinion in microbiology · 2017Review
- The Trophic Life Cycle Stage of the Opportunistic Fungal Pathogen Pneumocystis murina Hinders the Ability of Dendritic Cells To Stimulate CD4Infection and immunity · 2017Article
- Pulmonary Interleukin-17-Positive Lymphocytes Increase during Pneumocystis murina Infection but Are Not Required for Clearance of Pneumocystis.Infection and immunity · 2017Article
- Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.Infection and immunity · 2017Article
- An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia.American journal of respiratory cell and molecular biology · 2017Article
- The life cycle stages of Pneumocystis murina have opposing effects on the immune response to this opportunistic, fungal pathogen.Infection and immunity · 2016Article
- Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.The Journal of infectious diseases · 2016Article
- Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Characterization of chemokine and chemokine receptor expression during Pneumocystis infection in healthy and immunodeficient mice.Microbes and infection · 2015Article
- B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.Infection and immunity · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
To determine whether different antibody isotypes associated with T helper 1 (Th1) or Th2 responses are protective against Pneumocystis carinii, mice with disrupted interleukin 4 genes (IL-4(-/-) mice) or gamma interferon genes (IFN-gamma(-/-) mice) along with wild-type C57BL/6 mice were immunized intratracheally against P. carinii, depleted of T cells in vivo by use of monoclonal antibodies, and rechallenged intratracheally with 10(7) viable P. carinii organisms. Nearly all immunized mice resolved their lung P. carinii infections (limit of detection, log10 4.06) within 21 days of challenge even though they were depleted of T cells. Unimmunized mice depleted of T cells had significant lung infections (>log10 5.5) at day 21 post-P. carinii challenge. IFN-gamma(-/-) and wild-type mice developed P. carinii-specific immunoglobulin primarily of the immunoglobulin G1 (IgG1) subclass with relatively little P. carinii-specific IgG2a, IgG2b, or IgG3 in their sera, characteristic of a Th2-type response. In contrast, IL-4(-/-) mice had primarily an IgG2b P. carinii-specific antibody response in their sera with very little IgG1. Although IgG2b was the predominant isotype in IL-4(-/-) mice, optical density values of IgG2a and IgG3 were significantly higher in these mice (two and three times, respectively) than in IFN-gamma(-/-) mice, characteristic of a Th1-type response. Together, these data indicate that resolution of P. carinii infection can be mediated by specific antibody responses and that the antibody response can be either a predominantly Th1 or Th2 type. Furthermore, although wild-type mice mounted a Th2-like antibody response, IL-4(-/-) mice could resolve P. carinii pneumonia, indicating that resistance to P. carinii can occur in the absence of IL-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.